Partnerships

Driven by our strategy to rapidly advance unique, high quality compounds successfully through the clinic, Vitae Pharmaceuticals actively embraces strategic partnerships in all aspects of its business.

We seek collaborations with leading pharmaceutical companies to enhance two aspects of our pipeline development. First, we look for partnerships to provide additional resources to our priority programs to accelerate development and commercialization of our product candidates. Second, we look for partnership opportunities that leverage the value of our intellectual property assets which include specific expertise and a significant patent estate.

We operate with the firm belief that significant advances in drug discovery, development, and commercialization must come from both inside and outside our company. By selectively and strategically combining ideas and resources with our partners, we can more quickly and effectively develop important drugs for unmet medical needs and bring them to patients sooner.

Boehringer Ingelheim GmbH

In October 2007, we formed a strategic alliance with Boehringer Ingelheim (BI) around our 11ß-HSD-1 inhibitor program. With BI, we have an exclusive, worldwide strategic partnership to develop and commercialize novel compounds for patients with diabetes and related metabolic disease conditions, such as dyslipidemia, obesity and hypertension. The alliance encompasses multiple series of novel, orally available 11ß-HSD-1 inhibitors discovered by Vitae Pharmaceuticals using our proprietary structure based design platform. Vitae Pharmaceuticals and BI have combined programs and jointly selected compounds for further development. Under the agreement, BI leads and funds development and commercialization of 11ß-HSD-1 inhibitors. Vitae Pharmaceuticals retains the right to develop compounds independently for certain indications outside of the core focus of diabetes and related metabolic conditions. Vitae Pharmaceuticals received an initial cash payment, equity investment, and research funding. In addition, Vitae Pharmaceuticals is eligible to receive up to $300 million in additional payments upon achievement of success-based milestones. Further milestones may be achieved with additional compounds or approved indications. BI also will pay Vitae Pharmaceuticals royalties on the sale of all products related to the program.  To date, Vitae Pharmaceuticals has earned $63 million under the collaboration.

Download press release of 11ß-HSD-1 collaboration

In June 2009, we established our second strategic alliance with Boehringer Ingelheim (BI) around our beta secretase (BACE) program. Similar to our successful diabetes partnership, this alliance is an exclusive, worldwide strategic collaboration to discover, develop and commercialize novel compounds for the treatment of Alzheimer's disease. Building on Vitae Pharmaceuticals’ rapidly advancing program, BI and Vitae Pharmaceuticals are working jointly to optimize compounds targeting BACE suitable for clinical development. BI will lead the development and commercialization of selected compounds. Under the agreement, Vitae Pharmaceuticals received initial cash and near term payments of $42 million. In addition, Vitae Pharmaceuticals will be eligible to receive $200 million in pre-commercial milestone payments based on the achievement of clinical and regulatory goals, as well as further milestone payments based on potential additional compounds and/or other approved indications. Vitae Pharmaceuticals will receive commercial performance payments and royalties from Boehringer-Ingelheim on all future product sales related to the program.

Download press release of BACE collaboration

Vitae Pharmaceuticals is actively pursuing development of VTP-27999, its wholly-owned direct renin inhibitor in Phase 1 clinical trials for chronic kidney disease, and will seek a development and commercialization partner.